SUVN-D4010 is a potent, selective, brain penetrant and orally bioavailable 5-HT4 receptor partial agonist for the treatment of cognitive dysfunction associated with Alzheimer’s disease and other dementias. Suven submitted Investigational New Drug Application (IND) to US FDA to conduct Phase-1 clinical trial for Cognition in Alzheimer’s Disease. SUVN-D4010 may be potentially useful for treating Alzheimer’s disease, cognitive disorders, Attention deficit hyperactivity disorder, Parkinson’s and schizophrenia References:

纯度：≥98%

CAS：1428862-32-1